JP2023542924A5 - - Google Patents

Info

Publication number
JP2023542924A5
JP2023542924A5 JP2023518145A JP2023518145A JP2023542924A5 JP 2023542924 A5 JP2023542924 A5 JP 2023542924A5 JP 2023518145 A JP2023518145 A JP 2023518145A JP 2023518145 A JP2023518145 A JP 2023518145A JP 2023542924 A5 JP2023542924 A5 JP 2023542924A5
Authority
JP
Japan
Prior art keywords
antibody
fusion protein
carboxypeptidase
cpb
bioreactor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023518145A
Other languages
English (en)
Japanese (ja)
Other versions
JP7808097B2 (ja
JP2023542924A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/051185 external-priority patent/WO2022066595A1/en
Publication of JP2023542924A publication Critical patent/JP2023542924A/ja
Publication of JP2023542924A5 publication Critical patent/JP2023542924A5/ja
Application granted granted Critical
Publication of JP7808097B2 publication Critical patent/JP7808097B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023518145A 2020-09-22 2021-09-21 治療タンパク質を生産するための方法 Active JP7808097B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063081380P 2020-09-22 2020-09-22
US63/081,380 2020-09-22
US202163225832P 2021-07-26 2021-07-26
US63/225,832 2021-07-26
PCT/US2021/051185 WO2022066595A1 (en) 2020-09-22 2021-09-21 Methods for producing therapeutic proteins

Publications (3)

Publication Number Publication Date
JP2023542924A JP2023542924A (ja) 2023-10-12
JP2023542924A5 true JP2023542924A5 (https=) 2024-10-01
JP7808097B2 JP7808097B2 (ja) 2026-01-28

Family

ID=78135186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518145A Active JP7808097B2 (ja) 2020-09-22 2021-09-21 治療タンパク質を生産するための方法

Country Status (6)

Country Link
US (1) US12486525B2 (https=)
EP (1) EP4217383A1 (https=)
JP (1) JP7808097B2 (https=)
KR (1) KR20230073270A (https=)
CN (1) CN116194570A (https=)
WO (1) WO2022066595A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202548027A (zh) * 2024-01-23 2025-12-16 美商安進公司 用於調節單株抗體電荷變體之方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5126250A (en) 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
WO1995019181A1 (en) 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0941344B1 (en) 1996-11-27 2004-05-19 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-vegf 항체
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2309012T3 (es) 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
PT2837680T (pt) 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
HUE035685T2 (en) 2011-11-02 2018-05-28 Hoffmann La Roche Overload and elute chromatography
DK2970994T3 (da) 2013-03-15 2019-10-28 Lonza Ag Konstitutiv promotor
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program
EP3699269A1 (en) 2015-09-22 2020-08-26 F. Hoffmann-La Roche AG Expression of fc-containing proteins
HRP20210830T1 (hr) 2016-10-17 2021-08-20 Enzene Biosciences Ltd. Kontinuirani proces smanjenja heterogenosti terapijskog proteina

Similar Documents

Publication Publication Date Title
US10711057B2 (en) Methods of shifting an isoelectric profile of a protein product and uses thereof
RU2580020C2 (ru) Способ снижения гетерогенности антител и способ получения соответствующих антител
US9206390B2 (en) Methods to control protein heterogeneity
JP2010536396A5 (https=)
KR20120107140A (ko) 면역글로불린 용액 정제 방법
JP6138788B2 (ja) 形質転換した微生物、例えばピキア・パストリス中で抗体などのマルチサブユニットタンパク質を高濃度かつ高純度で生産するための多コピー法
CN106536746A (zh) 用于生产蛋白的细胞培养方法
CN101413002A (zh) 表达抗体或抗体类似物的重组克鲁维酵母菌及其构建方法与应用
JP2023542924A5 (https=)
CN111647086B (zh) 一种重组小鼠抗人肌酸激酶单克隆抗体、制备方法和应用
JP2019115372A (ja) 細胞を培養する方法
CN106661117B (zh) IgG杂合型抗TNFα和IL-17A双特异性抗体
JP2024533319A5 (https=)
CN107849526A (zh) 调节重组蛋白生产样态的方法
US20160024203A1 (en) Methods of producing antibodies in yeast
WO2025088516A1 (en) Method of forming multi-specific antibodies from homodimer antibodies and pharmaceutical product including multi-specific antibodies thus obtained
JP2025533167A (ja) 組換えタンパク質産生のためのプロセス
Bhavsar et al. An Improved Cell Culture Process for Production of Omalizumab.
CN107849525A (zh) 调节重组蛋白生产样态的方法
CN111647083A (zh) 一种重组小鼠抗人血幼素单克隆抗体、制备方法和应用
CN119384514A (zh) 细胞培养方法
CN111116749A (zh) 重组的人源化gpc3抗体及其构建和应用
HK1238298A1 (en) Cell culture process for producing a protein